{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-068566","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.138607+00:00","generated_at":"2026-06-04T16:57:40.028906+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aileron CEO Manuel Aivado resigns; President Brian Windsor named CEO effective March 11, 2024","bullets":["Manuel Aivado steps down as CEO effective March 11, 2024, remains on the Board.","Brian Windsor, previously President and COO since October 2023, appointed CEO and director.","Windsor led Lung Therapeutics prior to its acquisition by Aileron in October 2023.","Aivado receives severance: 18 months base salary, 1.5x target bonus, equity acceleration, COBRA.","Resignation is not due to any disagreement with company operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-068566","json":"https://secwatch.observer/filing/0001193125-24-068566.json","markdown":"https://secwatch.observer/filing/0001193125-24-068566.md","text":"https://secwatch.observer/filing/0001193125-24-068566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/0001193125-24-068566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/d787456d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T16:57:40.028906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cea864ee4","claim":"Brian Windsor was elected as Chief Executive Officer at Rein Therapeutics, Inc..","evidence_excerpt":"the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/0001193125-24-068566-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"71466b2ae0","claim":"Manuel C. Alves-Aivado resigned as Chief Executive Officer at Rein Therapeutics, Inc..","evidence_excerpt":"Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/0001193125-24-068566-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ee28c27002","claim":"Brian Windsor was elected as Director at Rein Therapeutics, Inc..","evidence_excerpt":"the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/0001193125-24-068566-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}